The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
Ontology highlight
SUBMITTER: Vidal-Crespo A
PROVIDER: S-EPMC5664406 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA